Clinical Trial News and Research

RSS

Emergent BioSolutions commences NuThrax Phase 2 trial in anthrax infection

Emergent BioSolutions Inc. today announced the initiation of a Phase 2 clinical trial for NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject.

18 Jan 2013

Stroke patients with PTSD less likely to adhere to treatment regimens

A new survey of stroke survivors has shown that those with post-traumatic stress disorder (PTSD) are less likely to adhere to treatment regimens that reduce the risk of an additional stroke. Researchers found that 65 percent of stroke survivors with PTSD failed to adhere to treatment, compared with 33 percent of those without PTSD.

18 Jan 2013

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

A groundbreaking, international clinical trial of an iron chelation drug, deferiprone, to treat the rare and devastating neurodegenerative disease, pantothenate kinase-associated neurodegeneration (PKAN), began last month at the trial's only North American site, Children's Hospital & Research Center Oakland.

17 Jan 2013

Researchers identify potential sources of medicines derived from plants against diabetes

A group of researchers from the university's School of Science, led by Dr Solomon Habtemariam, believe they have identified potential sources of medicines derived from plants which may have fewer adverse side-effects for diabetes sufferers.

17 Jan 2013

Boston Scientific initiates Blazer Open-Irrigated Catheter clinical trial in atrial fibrillation

The first patient has been treated in the Boston Scientific Corporation ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer Open-Irrigated Temperature Ablation Catheter in patients with symptomatic, drug refractory paroxysmal atrial fibrillation.

17 Jan 2013

AeriSeal System may provide relief for patients with emphysema

Those who have emphysema may soon be able to breathe a sigh of relief. That's because alternative ways to treat advanced cases of the condition are being developed.

17 Jan 2013

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).

17 Jan 2013

GE Healthcare submits Optison sNDA to aid in detection of cardiovascular diseases

GE Healthcare today announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility.

16 Jan 2013

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

16 Jan 2013

Update on Cytos’ CYT003 Phase 2b trial for allergic asthma

Cytos Biotechnology Ltd today announced an update on the Phase 2b clinical trial with its lead product candidate, CYT003, in allergic asthma.

16 Jan 2013

Aggressive breast cancer’s metastasis molecular switch identified

Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor and metastasize throughout the body. Their findings, published in Cancer Cell, suggest a novel approach for developing agents to treat cancer once it has spread.

15 Jan 2013

Mirena coil intrauterine device a better treatment for heavy menstrual periods

The hormone-releasing Mirena coil intrauterine device (IUD) is a better treatment for heavy menstrual periods than other conventional medical approaches, according to results of a major clinical trial led by scientists from the Universities of Nottingham and Birmingham.

11 Jan 2013

New guidelines to help fast track radiation oncology drug development

Researchers from the translational research program of the National Cancer Institute and the Radiation Therapy Oncology Therapy Group have developed new guidelines to help fast track the clinical development of targeted cancer drugs in combination with radiation therapy.

11 Jan 2013

TapImmune announces results from HER2/neu interim study on breast cancer

TapImmune Inc. has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events.

11 Jan 2013

Study compares three treatment approaches in membranous nephropathy

The results of a pioneering UK-wide clinical trial that compared treatments for patients with a common type of kidney disease has found one to be significantly more effective. The results of the study, published online in The Lancet, will be recommended to clinicians worldwide as the most effective approach to treating the condition.

10 Jan 2013

Fingolimod could potentially eliminate or reduce progression of colitis-associated cancer

After uncovering a mechanism that promotes chronic intestinal inflammation and the development of colorectal cancer, scientists from Virginia Commonwealth University Massey Cancer Center have found that fingolimod, a drug currently approved for the treatment of multiple sclerosis, could potentially eliminate or reduce the progression of colitis-associated cancer (CAC).

10 Jan 2013

VolitionRx to commence large internal clinical study for Nucleosomics diagnostic products

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests, announces that it will commence a large internal clinical study for its Nucleosomics diagnostic products this month.

9 Jan 2013

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

9 Jan 2013

CTI initiates enrollment in pacritinib Phase 3 trial for myelofibrosis

Cell Therapeutics, Inc. (CTI) today announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis.

9 Jan 2013

Lilly, Boehringer Ingelheim announce top-line results from empagliflozin Phase III trials on T2D

Boehringer Ingelheim and Eli Lilly and Company today announced top-line results for four completed Phase III clinical trials for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT2) inhibitor being studied for treatment of patients with Type 2 Diabetes (T2D).

9 Jan 2013

Clinical Trial News and Research

Emergent BioSolutions commences NuThrax Phase 2 trial in anthrax infection

Stroke patients with PTSD less likely to adhere to treatment regimens

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

Researchers identify potential sources of medicines derived from plants against diabetes

Boston Scientific initiates Blazer Open-Irrigated Catheter clinical trial in atrial fibrillation

AeriSeal System may provide relief for patients with emphysema

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

GE Healthcare submits Optison sNDA to aid in detection of cardiovascular diseases

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Update on Cytos’ CYT003 Phase 2b trial for allergic asthma

Aggressive breast cancer’s metastasis molecular switch identified

Mirena coil intrauterine device a better treatment for heavy menstrual periods

New guidelines to help fast track radiation oncology drug development

TapImmune announces results from HER2/neu interim study on breast cancer

Study compares three treatment approaches in membranous nephropathy

Fingolimod could potentially eliminate or reduce progression of colitis-associated cancer

VolitionRx to commence large internal clinical study for Nucleosomics diagnostic products

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

CTI initiates enrollment in pacritinib Phase 3 trial for myelofibrosis

Lilly, Boehringer Ingelheim announce top-line results from empagliflozin Phase III trials on T2D

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery